89 results about "Glycan metabolism" patented technology

The invention discloses a health-care beverage of guava. The health-care beverage is characterized by comprising the following substances and materials in parts by weight: 30-50 parts of guava, 20-40 parts of bitter gourd, 10-30 parts of Chinese yam, 20-40 parts of folium mori and 5-20 parts of American ginseng. The health-care beverage can be made into dosage forms of tablets, capsules, granules, tea bags and the like; the health-care beverage tastes good, has the original flavor, has the pleasant tea fragrance, is applicable for long-term drinking of glycosuria patients, has the functions of conditioning the insulin secretion and promoting the glycometabolism and fat metabolism, and is capable of conditioning the physiological functions of glycosuria patients, recovering the normal functions of the spleen and stomach and achieving the functions of blood sugar reduction, fat reduction, and glycosuria adjuvant therapy; and when being drunk or taken by ordinary people, the health-care beverage also has the functions of promoting the human body conditioning ability and ensuring the health.

Provided is a construction method of an escherichia coli genetically engineered bacteria producing succinic acid by xylose metabolism and the method for producing succinic acid by fermentation using the bacteria. The ATP biosynthesis pathway of escherichia coli is modified by means of molecular biology and the enzyme activity related to the pathway is over-expressed; thus the total ATP amount within escherichia coli cells is effectively increased such that the recombinant escherichia coli is able to grow using xylose metabolism, and the succinic acid synthesis efficiency is thereby significantly improved.

The invention provides a genetic engineering bacterium strain for producing succinic acid. The genetic engineering bacterium strain is named as Escherichia coli BA016, the preserving number registration number CCTCC NO is M 2012350. The invention further provides a construction method of the strain and a method for producing succinic acid by fermentation, recombinant escherichia coli can grow by glucose metabolism through joint excessive expression of exogenous pyruvic carboxylase and nicotinic acid ribose phosphate transferase, generation of by-product pyruvic acid is reduced, and accordingly the yield and production intensity of succinic acid are greatly improved.

The invention provides a CectGPDH2 gene and an application thereof in increase of fatty acid content. The nucleotide sequence of the CectGPDH2 gene is shown as SEQ NO.1. The gene comes from Chlorella ellipsoidea and encodes GPDH, wherein the GPDH participates in shuttle of the mitochondrion G3P (glycerol-3-phosphate), provides electrons for respiratory chains, is a key enzyme for G3P synthesis, is one of the key enzymes for connecting glucose metabolism with lipid metabolism and plays an important role in lipid synthesis and energy metabolism in plants. The total fatty acid content of seeds of Arabidopsis thaliana and rape genetically modified with the gene can be increased obviously, and the gene can be used for increasing the oil content of plant cells and the content of linoleic acid (C18:2) and eicosenoic acid (C20:1) in the plants and has good application prospect.

The invention provides a Cem GPDH (Glycerol-3-phosphate dehydrogenase) gene and an application of the Cem GPDH gene in the aspect of increase of cellular fatty acid content. A nucleotide sequence of the Cem GPDH gene is represented as SEQ ID NO: 1. The gene is derived from Chlorella ellipsoidea, and GPDH is coded. G3P (Glycerol-3-phosphate) synthesized through catalysis by GPDH is an important raw material for synthesis of TAG (triacylglycerol), the enzyme participates in mitochondria G3P shuttle, provides electrons for a respiratory chain, is a key enzyme for G3P synthesis, is one of key enzymes for connecting glycometabolism and lipid metabolism and has an important effect on lipid synthesis and energy metabolism in plants; and besides, the gene can remarkably increase the total fatty acid content of cells when utilized to convert yeast cells, plant cells and microalgae cells.

This invention provides a method for measuring glucose metabolism ability of a subject and a composition that is suitably used in the method. The method for measuring glucose metabolism ability of the present invention is as follows: a method for measuring glucose metabolism ability of a subject, using a composition for measuring glucose metabolism ability, the composition comprising, as an active ingredient, glucose labeled with at least one isotope of C, wherein the glucose is converted in the body into labeled carbon dioxide that is excreted in expired air, the method comprising steps (a) and (b) below:

• (a) administering the composition to the subject and collecting expired air; and
• (b) determining the ratio of labeled CO₂ amount to unlabeled CO₂ amount or the ratio of labeled CO₂ amount to total CO₂ amount.

The present invention relates to a nucleic acid molecule comprising a chromosomal region contributing to or indicative of hyperlipidemias and/or dyslipidemias or defective carbohydrate metabolism, wherein said nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence has one or more mutations having an effect on USFI function; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence is characterized by comprising a guanine or an adenine residue in position 3966 in intron 7 of the USF1 sequence; and/or (c) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence is characterized by comprising a cytosine or a thymine residue in position 5205 in, exon 11 of the USF1 sequence; wherein said nucleic molecule extends, at a maximum, 50000 nucleotides over the 5' and/or 3' end of the nucleic acid molecule of SEQ ID NO: 1. The present invention further relates to a diagnostic composition comprising a nucleic acid molecule encoding USF1 or a fragment thereof, the nucleic acid molecule disclosed herein, the vector, the primer or primer pair of the present invention or an antibody specific for USF1. Finally, the present invention relates to the use of the nucleic acid molecule of the invention for the preparation of a pharmaceutical composition for the treatment of hyperlipidemia, dyslipidemia, coronary heart disease, type II diabetes, metabolic syndrome, hypertension or atherosclerosis.

The invention discloses a method for quantitative determination of regeneration capability of 1,5-ribulose diphosphate. The method comprises the following steps: selecting the second, the third and the fourth completely spread leaves, performing non-destructive determination on apparent photosynthesis rate, taking a mean value of three leaves to represent the apparent photosynthesis rate PN of the plant; then taking the leave which has measured apparent photosynthesis rate, shearing the leave and fully mixing the leave, taking 0.1 g of the material for enzyme liquid extraction; respectively determining the phosphofructokinase vitality and glucose-6-phosphate dehydrogenase enzyme vitality expressed by the change value at unit volume and unit time in the extracted enzyme liquid, calculating phosphopentose pathway proportion in the glycometabolism according to a formula, and then multiplying by the apparent photosynthesis rate of the plant leave to obtain the regeneration capability of 1,5-ribulose diphosphate. The method can realize rapid quantitative determination of the regeneration capability of 1,5-ribulose diphosphate, and has the advantages of less step, simple calculation, and comparability and reliability of the determination result.

The invention belongs to the field of glucosamine production, and relates to a production method of glucosamine. The production method comprises the steps of: in the glucosamine fermentation process,monitoring at least one of an oxygen consumption rate, an oxidation-reduction potential, acetic acid concentration and a specific carbon dioxide release rate in fermentation liquor on line, and controlling the numerical value within a specific range by stages. According to the method provided by the invention, at least one of the oxygen consumption rate, the oxidation-reduction potential, the acetic acid concentration and the specific carbon dioxide release rate in the fermentation liquor is monitored and controlled on line to feed back process parameters of the regulation and control process,so that the thallus growth requirement can be met, glucosamine metabolic synthesis is effectively promoted, and the conversion rate is increased; and the content and conversion rate of the glucosamine in the obtained fermentation product are both high.

The invention discloses an application of a lactalbumin-oleic acid composite to preparation of medicines for restraining energy metabolism of tumor cells, and finds that alpha-LA-OA can resist the glycolysis process of tumor cells and reduce the consumption of oxygen by an aerobic respiration process of a mitochondrion and the generation amount of ATP. In addition, the invention further finds thatthe alpha-LA-OA can reduce generation of ATP in an HepG2 cell glucose metabolism way, so that the effect of restraining energy metabolism of tumor cells can be achieved; an HepG2 tumor cell model isused for confirming that the alpha-LA-OA can notably promote expression of mTORC2 target protein Rictor, mSin1 and Ser473-Akt, and the expression amount of various enzymes in the glycolysis way can benotably reduced. The alpha-LA-OA can activate an mTORC2 signal route, and can restrain activity of key enzymes in the glucose metabolism way, so as to reduce the energy metabolism for restraining tumor cells, by ATP.

A composition, including: (A) Panax notoginseng; and at least one of (B) a Piper longum extract and (C) vitamin B1, a salt thereof or a derivative thereof.

Disclosed is an enzyme composition for regulating sugar metabolism which can regulate the absorption of glucose into the body by converting the carbohydrates in food to a form of sugar that is not absorbed in the stomach and the like before being decomposed in the small intestine into glucose by the activity of various enzymes such as maltase, sucrase, or lactase and the like and absorbed, wherein the enzyme composition includes: one or more enzymes selected from the group consisting of glucoamylase, sucrase and lactase; glucose oxidase; and transglucosidase.

The invention discloses a monoclonal antibody resistant to vole babesia. The monoclonal antibody is secreted by a hybridoma cell strain HA5-E4 having a collection number of CCTCC NO: 201835. Aiming atlactic dehydrogenase LDH in a glucide metabolic pathway of the vole babesia, the protein has immunogenicity, and a monoclonal antibody aiming at rBmLDH is prepared; Western blot detection proves thatthe monoclonal antibody is capable of specifically recognizing the vole babesia but cannot recognize the LDH of the host. Therefore, the monoclonal antibody can be applied to detection of vole babesia in infection cells through an immumofluorescence method.

The invention relates to the technical field of gene therapy or biological medicine, in particular to a nucleic acid construct for gene therapy of glycometabolism-related diseases; the nucleic acid construct comprises polynucleotide for coding GLP-1 or an analogue thereof; the total number of the GLP-1 or the analogue thereof is more than two; the GLP-1 and the GLP-1 are connected through polynucleotide for coding a connecting peptide; the GLP-1 and the analogue thereof are connected through the polynucleotide for coding the connecting peptide; or the analogue of the GLP-1, the GLP-1 and the analogue are connected through the polynucleotide for coding the connecting peptide. The nucleic acid construct disclosed by the invention can be used for efficiently expressing the GLP-1 with the activity and the analogue thereof in vivo and in vitro, so that a technical route is provided for developing medicines for treating glycometabolism-related diseases such as type 2 diabetes, body metabolic disorder, diabetes-related complications and obesity which have great potential.

The invention discloses a sugar control composition containing quinoa and preparation method thereof. The preparation method comprises the following steps: respectively weighing the following components in percentage by mass: 25-40% of quinoa, 10-20% of purple rice, 10-20% of white kidney beans, 10-20% of oats and 10-20% of walnuts, the sum of the mass percentages of the components being 100%; in the formula, vitamin B1 in the quinoa and coarse cereals in the formula can maintain normal glycometabolism and nerve conduction functions of diabetic patients, and can help diabetic patients to maintain capillary health and avoid microangiopathy; so that the composition is capable of improving the kidney cell metabolism disorder caused by hypertension, wherein magnesium can better help the blood sugar of the diabetic patient to be converted into energy, and meanwhile insulin response is improved. In addition, the n-3 series of polyunsaturated fatty acids in the walnuts can help and enhance cell activity, then increase insulin receptors, make insulin very sensitive, increase blood sugar consumption and convert blood sugar into glycogen.

The invention discloses a method for preparing a Kinase protein Akt1 conditional gene knockout non-human mammal model and application of the method. The invention further discloses a method for screening compounds for preventing or treating cardiomegaly and glucose metabolic disorders by the Kinase protein Akt1 conditional gene knockout non-human mammal model, and application of the model that Akt1 and upstream and downstream biological signal transduction pathways of the Akt1 serve as medicine intervention targets to treat cardiomegaly and glucose metabolic disorders.

The invention relates to the technical field of animal model establishment, in particular to a non-alcoholic fatty liver animal model and an establishment method. The animal model is established by adopting an NR4A1-/-gene knockout mouse. The NR4A1-/-gene knockout mouse is adopted to establish the non-alcoholic fatty liver animal model, the relationship between the NR4A1-/-gene and glycometabolism and fat metabolism of the liver is fully utilized, the glycolipid metabolism of the NR4A1-/-gene knockout mouse is disturbed, and fat can be deposited on the liver after high-fat feeding, so that the non-alcoholic fatty liver is formed; the method is simple to operate and obvious in effect. The animal model has the characteristics of obesity, dyslipidemia and the like, and has high similarity with NAFLD clinical pathology.

The invention provides a method for improving insulin secretion of pancreatic islet cells through gene modification. The pancreatic related cells are modified by adopting an ERRgamma gene. According to the invention, specific ERRgamma protein is brought into pancreatic islet cells to activate glycometabolism-related pathways, so that the content of ERRgamma protein secreted by pancreatic islet cells and the amount of insulin are increased. The pancreatic islet cells are obtained by culturing 7-9 pancreatic related cells infected by the virus containing the ERR gamma gene, and the content of secreted ERR gamma protein is 3.2-3.5 ng/ml; the content of insulin secreted under the stimulation of 22mmol of glucose is 71.2-75 ng/ml, and the content of insulin secreted under the stimulation of 2mmol of glucose is 11.6-12 ng/ml.